Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Kazia Therapeutics Limited (KZIA)

1   -0.01 (-0.99%) 01-27 15:58
Open: 1 Pre. Close: 1.01
High: 1.04 Low: 0.97
Volume: 32,193 Market Cap: 19(M)

Technical analysis

as of: 2023-01-27 4:45:56 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 1.22     One year: 1.43
Support: Support1: 0.71    Support2: 0.5
Resistance: Resistance1: 1.04    Resistance2: 1.22
Pivot: 0.97
Moving Average: MA(5): 1     MA(20): 0.9
MA(100): 0.89     MA(250): 3.53
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 84.7     %D(3): 86.4
RSI: RSI(14): 63.9
52-week: High: 8.6  Low: 0.5
Average Vol(K): 3-Month: 78 (K)  10-Days: 65 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ KZIA ] has closed below upper band by 41.3%. Bollinger Bands are 9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.04 - 1.05 1.05 - 1.05
Low: 0.96 - 0.96 0.96 - 0.97
Close: 0.99 - 1 1 - 1.01

Company Description

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Headline News

Fri, 27 Jan 2023
Kazia Therapeutics Limited (KZIA) Stock Price Today, Quote & News - Seeking Alpha

Tue, 17 Jan 2023
Neovasc, Aligos top healthcare gainers; Edesa, Angion lead losers ... - Seeking Alpha

Mon, 16 Jan 2023
KAZIA ANNOUNCES PLACEMENT OF A$4.5MILLION AND ... - Marketscreener.com

Mon, 16 Jan 2023
KAZIA RAISES A$4.5 MILLION TO PROGRESS R&D PROGRAMS - PR Newswire

Mon, 16 Jan 2023
KAZIA raises A$4.5M TO PROGRESS R&D PROGRAMS (NASDAQ ... - Seeking Alpha

Mon, 19 Dec 2022
Kazia Therapeutics (KZIA): Collaboration May Expand Utility to ... - StreetInsider.com

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 15 (M)
% Held by Insiders 1.195e+007 (%)
% Held by Institutions 0 (%)
Shares Short 180 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -2.291e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -248
Return on Assets (ttm) 657
Return on Equity (ttm) -33.5
Qtrly Rev. Growth 10000
Gross Profit (p.s.) -49.27
Sales Per Share -43
EBITDA (p.s.) 4926.1
Qtrly Earnings Growth -0.9
Operating Cash Flow 0 (M)
Levered Free Cash Flow -23 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.03
Price to Cash Flow 1.51

Stock Dividends

Dividend 0
Forward Dividend 163330
Dividend Yield 0%
Dividend Pay Date 2017-07-13
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.